A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 569-574

  Garcia, Agustin A ^a   Sill, Michael W ^b   Lankes, Heather A ^b   Godwin, Andrew K ^c   Mannel, Robert S ^d   Armstrong, Deborah K ^e   Carolla, Robert L ^f   Liepman, Marcia K ^g   Spirtos, Nick M ^h   Fischer, Edgar G ⁱ   Leslie, Kimberly K ^j  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Cancer Research for the Ozarks   (United States)

^g West Michigan Cancer Center   (United States)

^h Women's Cancer Center of Nevada   (United States)

ⁱ UNIVERSITY OF NEW MEXICO   (United States)

^j UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

more..

Author keywords

Epidermal growth factor receptor (EGFR); Ki 67; Lapatinib; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LAPATINIB;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; EPITHELIAL OVARIAN CANCER; EXON; EYE TOXICITY; FATIGUE; FEMALE; GENE MUTATION; HEARING IMPAIRMENT; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHY; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; SKIN DISEASE; THROMBOCYTOPENIA; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POLYMORPHISM, GENETIC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856702658     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.10.022     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin 60 2010 277 300
2. M. Harries, and M. Gore Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease Lancet Oncol 3 2002 537 545
3. O. Alper, M.L. De Santis, K. Stromberg, N.F. Hacker, Y.S. Cho-Chung, and D.S. Salomon Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells Int J Cancer 88 2000 566 574
4. O. Alper, E.S. Bergmann-Leitner, T.A. Bennett, N.F. Hacker, K. Stromgberg, and W.G. Stetler-Stevenson Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells J Natl Cancer Inst 93 2001 1375 1384
5. M. Campiglio, S. Ali, P.G. Knyazev, and A. Ullrich Characteristics of EGFR family-mediated HRG signals in human ovarian cancer J Cell Biochem 73 1999 522 532
6. R.C. Bast Jr., L. Pusztai, B.J. Kerns, J.A. MacDonald, P. Jordan, and L. Daly Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues Hybridoma 17 1998 313 321
7. J.M. Bartlett, S.P. Langdon, B.J. Simpson, M. Stewart, D. Katsaros, and P. Sismondi The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer Br J Cancer 73 1996 301 306
8. A. Berchuck, A. Kamel, R. Whitaker, B. Kerns, G. Ott, and R. Kinney Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 1990 4087 4091
9. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, and D.E. Keith Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
10. D. Ye, J. Mendelsohn, and Z. Fan Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 Oncogene 18 1999 731 738
11. S.D. Pack, O.M. Alper, K. Stromberg, M. Augustus, M. Ozdemirli, and A.K. Miermont Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line Cancer Res 64 2004 789 794
12. J.A. Wilken, K.T. Webster, and N.J. Maihle Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics J Ovarian Res 27 2010 3 7
13. N. Takai, A. Jain, N. Kawamata, L.M. Popoviciu, J.W. Said, and S. Whittaker 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth Cancer 104 2005 2701 2708
14. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, and S.H. Dickerson A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 2004 6652 6659
15. D.W. Rusnak, K. Affleck, S.G. Cockerill, C. Stubberfield, R. Harris, and M. Page The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res 61 2001 7196 7203
16. W. Xia, R.J. Mullin, B.R. Keith, L.H. Liu, H. Ma, and D.W. Rusnak Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 2002 6255 6263
17. K.L. Blackwell, M.D. Pegram, E. Tan-Chiu, L.S. Schwartzberg, M.C. Arbushites, and J.D. Maltzman Single-agent lapatinib for HER2-overerexpression advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens Ann Oncol 20 2009 1026 1031
18. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. M. Singh, R.J. Zaino, V.J. Filiaci, and K.K. Leslie Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 106 2007 325 333
20. R. Schilder, M. Sill, X. Chen, K.M. Darcy, S.L. Decesare, and G. Lewandowski Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study Clin Cancer Res 11 2005 5539 5548
21. T.T. Chen, and T.H. Ng Optimal flexible designs in phase II clinical trials Stat Med 17 1998 2301 2312
22. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assn 53 1958 457 481
23. M.G. Kendall The treatment of ties in rank problems Biometrika 33 1945 239 251
24. C. Spearman The proof and measurement of association between two things Am J Psychol 15 1904 72 101
25. Fisher RA. Statistical methods for research workers. Edinburgh, Oliver and Boyd, 1934, 1970.
26. C.R. Mehta, and N.R. Patel A network algorithm for performing Fisher's exact test in r × c contingency tables J Am Stat Assoc 78 1983 427 434
27. D.R. Cox Regression models and life tables J Royal Stat Soc Ser B 34 1972 187 220
28. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby, and I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group J Clin Oncol 21 2003 283 290
29. A.N. Gordon, N. Finkler, R.P. Edwards, A.A. Garcia, M. Crozier, and D.H. Irwin Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 2005 785 792
30. E.M. Posadas, M.S. Liel, V. Kwitkowski, L. Minasian, A.K. Godwin, and M.M. Hussain A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer Cancer 109 2007 1323 1330
31. R.J. Schilder, H.B. Pathak, A.E. Lokshin, R.W. Holloway, R.D. Alvarez, and C. Aghajanian Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash Gynecol Oncol 113 2009 21 27
32. M.S. Gordon, D. Matei, C. Aghajanian, U.A. Matulonis, M. Brewer, and G.F. Fleming Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status J Clin Oncol 24 2006 4324 4332
33. S. Makhija, L.C. Amler, D. Glenn, F.R. Ueland, M.A. Gold, and D.S. Dizon Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J Clin Oncol 28 2010 1215 1223